The Diagnostic Value of Prostate Targeted Puncture Guided by MRI Combined with Ultrasound Fusion Imaging in Prostate Cancer with PI-RADS Score ≥3 Points

doi:10.7517/issn.1674-0475.200717

Abstract

Abstract: In order to explore the diagnostic value of prostate targeted puncture guided by MRI combined with ultrasound fusion imaging (MR-TRUS) in patients with prostate cancer of PI-RADS score ≥ 3 points, 100 patients who sought medical care in our hospital were enrolled. All of them were performed targeted biopsy via both MR-TRUS guided puncture and traditional puncture. And all the patients were tested the level of prostate specific antigen (PSA). According to 450 μg/L, the MR-TRUS guided puncture group (group A) and the traditional puncture group (group B) were both divided into 4 subgroups. The sensitivity, specificity and accuracy of different puncture methods for the diagnosis of prostate cancer were compared according to the postoperative pathological results. The results showed that the diagnostic rates of each subgroup in the group A were 28.57%, 66.67%, 70% and 91.67%, while the diagnostic rates of each subgroup in the group B were 9.52%, 25.00%, 60.00% and 86.11%, respectively. Compared with the traditional puncture method, MR-TRUS guided puncture significantly improved the diagnostic rate in patients of PSA ≤ 10 μg/L and 10P<0.05). The diagnostic rate of the two puncture methods was not significantly different in patients of 2050 μg/L (P>0.05). Compared with the traditional puncture method, the sensitivity and accuracy of MR-TRUS guided puncture were significantly improved (P<0.05). In summary, patients of PSA ≤ 10 μg/L and 10

Key words: prostatic cancer, nuclear magnetic resonance, ultrasound fusion imaging, MR-TRUS, targeted puncture, diagnostic value

ZHANG Wei, SHI Chunmei, ZHANG Zhongxin, WANG Lin, ZHENG Bing. The Diagnostic Value of Prostate Targeted Puncture Guided by MRI Combined with Ultrasound Fusion Imaging in Prostate Cancer with PI-RADS Score ≥3 Points[J]. IMAGING SCIENCE AND PHOTOCHEMISTRY, 2021, 39(1): 96-100.

References

[1] Fourcade A, Payrard C, Tissot V, et al. The combination of targeted and systematic prostate biopsies is the best protocol for the detection of clinically significant prostate cancer[J]. Scandinavian Journal of Urology, 2018, 52(3):174-179.
[2] Maxeiner A, Kittner B, Blobel C, et al. Primary magnetic resonance imaging/ultrasonography fusion-guided biopsy of the prostate[J]. BJU International, 2018, 122(2):211-218.
[3] Maxeiner A, Stephan C, Durmus T, et al. Added value of multiparametric ultrasonography in magnetic resonance imaging and ultrasonography fusion-guided biopsy of the prostate in patients with suspicion for prostate cancer[J]. Urology, 2015, 86(1):108-114.
[4] Stabile A, Dell'Oglio P, De Cobelli F, et al. Association between prostate imaging reporting and data system (PI-RADS) score for the index lesion and multifocal, clinically significant prostate cancer[J].European Urology Oncology,2018,1(1):29-36.
[5] Lee A Y, Yang X Y, Lee H J, et al. Multiparametric MRI-ultrasound software fusion prostate biopsy-initial results using a stereotactic robotic assisted transperineal prostate biopsy platform comparing systematic versus targeted biopsy[J]. BJU International, 2020. https://doi.org/10.1111/bju.15118.
[6] Preisser F, Theissen L, Wenzel M, et al. Performance of combined magnetic resonance imaging/ultrasound fusion-guided and systematic biopsy of the prostate in biopsy-naive patients and patients with prior biopsies[J]. European Urology Focus, 2019. DOI:10.1016/j.euf.2019.06.015.
[7] Porpiglia F, DE Luca S, Passera R, et al. Multiparametric-magnetic resonance/ultrasound fusion targeted prostate biopsy improves agreement between biopsy and radical prostatectomy gleason score[J]. Anticancer Research, 2016, 36(9):4833-4839.
[8] John S, Cooper S, Breau R H, et al. Multiparametric magne-tic resonance imaging-transrectal ultrasound-guided cognitive fusion biopsy of the prostate:clinically significant cancer detection rates stratified by the prostate imaging and data reporting system version 2 assessment category[J]. Canadian Urological Association Journal, 2018, 12(12):401-406.
[9] Tavolaro S, Mozer P, Roupret M, et al. Transition zone and anterior stromal prostate cancers:evaluation of discriminant location criteria using multiparametric fusion-guided biopsy[J]. Diagnostic and Interventional Imaging, 2018, 99(6):403-411.
[10] Leyh-Bannurah S R, Kachanov M, Beyersdorff D, et al. Minimum magnetic resonance imaging-ultrasound fusion targeted biopsy cores needed for prostate cancer detection:mul-tivariable retrospective, lesion based analyses of patients treated with radical prostatectomy[J]. The Journal of Uro-logy, 2020, 203(2):299-303.
[11] Lai W J, Wang H K, Liu H T, et al. Cognitive MRI-TRUS fusion-targeted prostate biopsy according to PI-RADS classification in patients with prior negative systematic biopsy results[J]. Journal of the Chinese Medical Association, 2016, 79(11):618-624.
[12] Schaudinn A, Gawlitza J, Mucha S, et al. Comparison of PI-RADS v1 and v2 for multiparametric MRI detection of prostate cancer with whole-mount histological workup as refe-rence standard[J]. European Journal of Radiology, 2019, 116:180-185.
[13] 黄琛. 经会阴实时超声磁共振影像融合靶向前列腺穿刺在前列腺癌早期诊断的临床意义[D]. 苏州:苏州大学, 2018.
[14] Choi M H, Kim C K, Lee Y J, et al. Prebiopsy biparametric MRI for clinically significant prostate cancer detection with PI-RADS version 2:a multicenter study[J]. American Journal of Roentgenology, 2019, 212(4):839-846.
[15] Moradi A, Srinivasan S, Clements J, et al. Beyond the biomarker role:prostate-specific antigen (PSA) in the prostate cancer microenvironment[J]. Cancer Metastasis Reviews, 2019, 38(3):333-346.
[16] Schmidkonz C, Goetz T I, Kuwert T, et al. PSMA SPECT/CT with Tc-MIP-1404 in biochemical recurrence of prostate cancer:predictive factors and efficacy for the detection of PSMA-positive lesions at low and very-low PSA levels[J]. Annals of Nuclear Medicine, 2019, 33(12):891-898.
[17] Gregorio E P, Alexandrino A P, Schuquel I T A, et al. Seminal citrate is superior to PSA for detecting clinically signi-ficant prostate cancer[J]. Official Journal of The Brazilian Society of Urology, 2019, 45(6):1113-1121.
[18] Kearns J T, Holt S K, Wright J L, et al. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening[J]. Cancer, 2018, 124(13):2733-2739.
[19] Jyoti S K, Blacke C, Patil P, et al. Prostate cancer screening by prostate-specific antigen (PSA); a relevant approach for the small population of the Cayman Islands[J]. Cancer Causes & Control, 2018, 29(1):87-92.